Investing.com — Johnson & Johnson (NYSE:)’s ‘AAA’ credit rating, as determined by S&P Global Ratings, is now under review due to the company’s recent acquisition of Intra-Cellular Therapies (NASDAQ:) Inc. The acquisition is expected to raise Johnson & Johnson’s S&P Global Ratings-adjusted leverage to 1.4x, which surpasses the 1.0x downside trigger for the current rating.

S&P Global Ratings has placed Johnson & Johnson’s ‘AAA’ ratings on CreditWatch Negative, indicating potential downgrades. This decision reflects the expectation that the company’s leverage may occasionally exceed 1.0x, a level that is inconsistent with the current ‘AAA’ rating.

Despite this, projections suggest that Johnson & Johnson will lower its leverage to 1.1x by the end of 2025 and below 1.0x by the end of 2026. These predictions are based on the assumption that the company will continue to expand its business and carry out smaller acquisitions over the next two years.

Johnson & Johnson has a history of successful integration of acquisitions and maintaining conservative financial policies. The company has carried out numerous substantial mergers and acquisitions to enhance the competitive positions of its Innovative Medicine and MedTech franchises. Notably, Johnson & Johnson acquired medical device manufacturer Shockwave Medical (NASDAQ:) Inc. for $13.1 billion in the first half of 2024. This followed its acquisitions of Abiomed (NASDAQ:) for $16.6 billion in 2022 and cardiovascular medical device maker Laminar Inc. for $400 million in late 2023.

The acquisition of Intra-Cellular aligns with Johnson & Johnson’s strategy of completing moderate-size acquisitions to strengthen its portfolio and pipeline. This move enhances the company’s neuroscience franchise, adding CAPLYTA to its portfolio, along with several other early-stage development prospects. Intra-Cellular has also submitted an application for CAPLYTA to treat major depressive disorder, which could significantly expand its potential market.

S&P Global Ratings has previously stated that it could lower the rating on Johnson & Johnson if its leverage remains above 1x for more than a year. The decision to resolve the CreditWatch listing will be made after reviewing the company’s full-year 2024 performance, 2025 guidance, additional details regarding the transaction, and further clarity on the company’s financial policy regarding future mergers and acquisitions. The ongoing talcum powder litigation settlement’s impact on Johnson & Johnson’s net S&P Global Ratings-adjusted leverage will also be assessed.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.


Source link

Best Brokers

Unmatched trading fees, generous bonuses, top notch Regulation Frame.

T&Cs Apply

Risk disclosure: All investments involve a degree of risk of some kind. Trading financial derivative products comes with a high risk of losing money rapidly due to leverage.

Top-Tier Regulations. Unmatched Spreads and Commissions. Trading View is available.

T&Cs Apply

Financial Spread Trades and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84.7% of retail investor accounts lose money when trading CFDs with this provider.

Modern and Intuitive Interfaces, Solid Regulatory Frame, and excellent Trading Fees.

T&Cs Apply
Risk warning: Trading derivatives is highly speculative, carries an inherent risk of loss and is not suitable for all investors. Before trading, you are strongly advised to read and ensure that you understand the relevant risk disclosures and warnings.

Highly Regulated. Low Spreads and Commissions. Vast Account Options.

T&Cs Apply

Risk Warning: Trading derivatives carries significant risks. It is not suitable for all investors and if you are a professional client, you could lose substantially more than your initial investment.